Predictors of Hematologic Malignancy Relapse in Patients with Advanced Chronic Graft-versus-Host Disease

[1]  G. Tonon,et al.  Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation , 2019, Nature Medicine.

[2]  J. Troy,et al.  Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  Anurag K Singh,et al.  Allogeneic Stem Cell Transplantation: A Historical and Scientific Overview. , 2016, Cancer research.

[4]  J. Wagner,et al.  Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  B. Andersson,et al.  Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[7]  Tao Wang,et al.  Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Yu-Hong Chen,et al.  Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  M. Marcatti,et al.  Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation , 2014, Leukemia.

[10]  N. Kröger,et al.  Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis , 2014, Leukemia.

[11]  J. Klein,et al.  Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia , 2014, Clinical Cancer Research.

[12]  S. Choi,et al.  Current and emerging strategies for the prevention of graft-versus-host disease , 2014, Nature Reviews Clinical Oncology.

[13]  M. Horowitz,et al.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. , 2014, Blood.

[14]  M. Sormani,et al.  Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors , 2012, Bone Marrow Transplantation.

[15]  S. Steinberg,et al.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity , 2011, Leukemia.

[16]  D. Porter,et al.  Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. , 2011, Blood.

[17]  A. Barrett,et al.  Relapse after allogeneic stem cell transplantation , 2010, Expert review of hematology.

[18]  N. Kröger,et al.  Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  N. Leidy,et al.  Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD) , 2010, Bone Marrow Transplantation.

[20]  R. Storb,et al.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Federica Torri,et al.  Loss of mismatched HLA in leukemia after stem-cell transplantation. , 2009, The New England journal of medicine.

[22]  E. Waller,et al.  Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. , 2009, Immunotherapy.

[23]  R. Schlenk,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[24]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[25]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[26]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  J. S. San Miguel,et al.  Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation , 2005, British journal of haematology.

[29]  J. Miguel,et al.  Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation. , 2004 .

[30]  S. Iacobelli,et al.  Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. , 2002, Blood.

[31]  T. Klingebiel,et al.  Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL , 2002, Leukemia.

[32]  John P Klein,et al.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. , 2002, Blood.

[33]  G. Morgan,et al.  An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation. , 2000, Cytotherapy.

[34]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[35]  R. Larson,et al.  Long‐term follow‐up of cancer and leukemia group B studies in acute myeloid leukemia , 1997, Cancer.

[36]  K. Rai,et al.  The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 years , 1989, British journal of haematology.

[37]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.